AZ5576

CAS No. 2751721-40-9

AZ5576( —— )

Catalog No. M35347 CAS No. 2751721-40-9

AZ5576, a potent and highly selective CDK9 inhibitor, can be used for research on Hematological Malignancy .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 75 In Stock
5MG 69 In Stock
10MG 109 In Stock
25MG 221 In Stock
50MG 325 In Stock
100MG 464 In Stock
200MG Get Quote In Stock
500MG 918 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AZ5576
  • Note
    Research use only, not for human use.
  • Brief Description
    AZ5576, a potent and highly selective CDK9 inhibitor, can be used for research on Hematological Malignancy .
  • Description
    AZ5576 is a potent and highly selective CDK9 inhibitor (IC50: <5 nM). AZ5576 can be used for hematological Malignancy research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2751721-40-9
  • Formula Weight
    385.43
  • Molecular Formula
    C21H24FN3O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (324.31 mM; Ultrasonic )
  • SMILES
    COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@H](C2)NC(C)=O)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bernard Barlaam, et al. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. ?
molnova catalog
related products
  • Cdc7-IN-5

    Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase. Cdc7, a serine-threonine protein kinase enzyme, is essential for the initiation of DNA replication in the cell cycle.

  • T025

    T025 is a pan CLK inhibitor with Kds of 4.8, 0.096, 6.5, 0.61, and 0.074 nM for CLK1-4, respectively.

  • Atuveciclib

    Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1.